Challenging Case Review: Non-Small Cell Lung Cancer
As a result of the therapeutic advances and clinical research affecting the management of patients with non-small cell lung cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this program, participants should be able to:
- Identify clinical challenges in managing patients with non-small cell lung cancer.
- Develop an evidence-based approach for the management of patients with non-small cell lung cancer.
Thomas J. Dilling, MD, MS
Moffitt Cancer Center
Sandip P. Patel, MD
UC San Diego Moores Cancer Center
Stephen C. Yang, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Thomas J. Dilling, MD, MS
AstraZeneca Pharmaceuticals LP: Consulting Fee
Sandip P. Patel, MD
Amgen Inc.: Grant/Research Support; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Fate Therapeutics: Grant/Research Support
Genentech, Inc.: Grant/Research Support; Scientific Advisor
Iovance Biotherapeutics: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novartis Pharmaceuticals Corporation: Grant/Research Support; Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
SQZ Biotech, Inc.: Grant/Research Support
Stephen C. Yang, MD
Intuitive: Product/Speakers Bureau
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.25 contact hours, 1.25 of which are pharmacotherapeutic contact hours.
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-22-060-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until March 1, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 ANCC Pharmacology Contact Hours
- 1.25 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing